Eight companies spearheading Philadelphia’s thriving biotech ecosystem
This issue of our newsletter is supported by Inpart.
As the largest city in Pennsylvania, Philadelphia has rapidly emerged as a major biotech hub.
In fact, it is often referred to as “Cellicon Valley” thanks to its significant contributions to cell and gene therapy.
The city’s strategic location along the U.S. Northeast corridor offers easy access to major markets, investors, and collaborators.
This makes it an attractive base for biotech companies.
So, would you like to discover eight of the biotech companies spearheading Philadelphia’s biotech ecosystem?
To find out more, read the full article: “Eight companies spearheading Philadelphia’s biotech industry”
A MESSAGE FROM OUR SPONSOR INPART
Upcoming Webinar: How J&J Accelerates Innovation
Join J&J VP Early Innovation Partnering Ajay Gautam on Tuesday, 28 May at 4pm CEST/10am ET to learn how J&J assesses biotech partners, what innovations they are targeting, and how to position your biotech for partnering success.
🔥 More noteworthy articles from this week:
IgA nephropathy - a chronic kidney disease - still doesn’t have a cure, but there have been plenty of advancements in the field recently. As we observed IgA Nephropathy Awareness Day on May 14, we took a look at drug approvals and ongoing clinical trials for new treatment options that aim to make patients’ lives better.
Coming under the area of regenerative medicine, orthobiologics is a rapidly advancing field that offers new options to treat acute orthopedic injuries and chronic or degenerative conditions without surgery. Here, we take a look at five companies leading the way in this area.
As the biotech sector continues to grow, driven by rapid advancements in technology and an increasing focus on personalized medicine, the variety of clinical trial designs is expanding. In this article, we delve into the essentials of clinical trial designs and emerging models.
As LinkedIn is an interesting tool - and could be the most powerful one at your disposal to develop your career - in this article we focus on how to efficiently leverage the site in your biotech job search and career development.
Isarna Therapeutics is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology - transforming growth factor beta (TGF-B) signaling. This week, we talked to René Rückert, chief operating officer at Isarna Therapeutics, who explained TGF-B and antisense oligonucleotides’ role in tackling disease.
In the realm of biotechnology, the use of mammalian cell lines has emerged as a cornerstone in the production of vital biotherapeutics and vaccines. Here, we dive into the key characteristics of mammalian cell lines that have earned them their critical role in the development of biologics.
2024 LABIOTECH READER SURVEY
🎁 Participate in the 2024 Labiotech Reader Survey for a chance to win a €250 or $250 Amazon gift card!
Your feedback matters. Take 5 minutes to share your insights and help us shape the future of Labiotech!
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.